Duvakitug

Duvakitug (TEV-48574) is a humanized IgG1-λ2 monoclonal antibody targeting to TNFSF15/TL1A. Duvakitug' main expression system is CHOK1SV cells endogenously expressing glutamine synthetase (GS). Duvakitug can be used in the study of Crohn's Disease (CD)[1][2].

[1] Gonsky, et al. Intestinal mononuclear phagocytes as prognostic biomarker for Crohn's disease. World Intellectual Property Organization, WO2023102051 A1. 2023-06-08.
[2] Duvakitug. IMGT/mAb-DB.
[3] Reinisch W, et al. OP41 Duvakitug (TEV-48574), an anti-TL1a monoclonal antibody, demonstrates efficacy and favourable safety as an induction treatment in adults with moderately to severely active ulcerative colitis: Results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging, basket trial (RELIEVE UCCD)[J]. Journal of Crohn's and Colitis, 2025, 19(Supplement_1): i79-i80.